Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the ESPGHAN committee on nutrition

Mihatsch, Walter A; Braegger, Christian; Bronsky, Jiri; Campoy, Cristina; Domellöf, Magnus; Fewtrell, Mary; Mis, Nataša F; Hojsak, Iva; Hulst, Jessie; Indrio, Flavia; Lapillonne, Alexandre; Mlgaard, Christian; Embleton, Nicholas; van Goudoever, Johannes; ESPGHAN Committee on Nutrition

Abstract: Vitamin K deficiency bleeding (VKDB) due to physiologically low vitamin K plasma concentrations is a serious risk for newborn and young infants and can be largely prevented by adequate vitamin K supplementation. The aim of this position paper is to define the condition, describe the prevalence, discuss current prophylaxis practices and outcomes, and to provide recommendations for the prevention of VKDB in healthy term newborns and infants. All newborn infants should receive vitamin K prophylaxis and the date, dose, and mode of administration should be documented. Parental refusal of vitamin K prophylaxis after adequate information is provided should be recorded especially because of the risk of late VKDB. Healthy newborn infants should either receive 1 mg of vitamin K1 by intramuscular injection at birth; or 3 × 2 mg vitamin K1 orally at birth, at 4 to 6 days and at 4 to 6 weeks; or 2 mg vitamin K1 orally at birth, and a weekly dose of 1 mg orally for 3 months. Intramuscular application is the preferred route for efficiency and reliability of administration. The success of an oral policy depends on compliance with the protocol and this may vary between populations and healthcare settings. If the infant vomits or regurgitates the formulation within 1 hour of administration, repeating the oral dose may be appropriate. The oral route is not appropriate for preterm infants and for newborns who have cholestasis or impaired intestinal absorption or are too unwell to take oral vitamin K1, or those whose mothers have taken medications that interfere with vitamin K metabolism. Parents who receive prenatal education about the importance of vitamin K prophylaxis may be more likely to comply with local procedures.

DOI: https://doi.org/10.1097/MPG.0000000000001232
Prevention of Vitamin K Deficiency Bleeding in Newborn Infants: A Position Paper by the ESPGHAN Committee on Nutrition

*Walter A. Mihatsch, †Christian Braegger, ‡Jiri Bronsky, §Cristina Campoy, ‡‡Magnus Domellöf, *Mary Fewtrell, ††Nataša F. Mis, **Iva Hojsak, †††Jessie Hulst, †††Flavia Indrio, $§§Alexandre Lapillonne, ###Christian Molgaard, ####Nicholas Embleton, and #######Johannes van Goudoever, ESPGHAN Committee on Nutrition

ABSTRACT

Vitamin K deficiency bleeding (VKDB) due to physiologically low vitamin K plasma concentrations is a serious risk for newborn and young infants and can be largely prevented by adequate vitamin K supplementation. The aim of this position paper is to define the condition, describe the prevalence, discuss current prophylaxis practices and outcomes, and to provide recommendations for the prevention of VKDB in healthy term newborns and infants. All newborn infants should receive vitamin K prophylaxis at birth, and a weekly dose of 1 mg orally for 3 months. Intramuscular application is the preferred route for efficiency and reliability of administration. The success of an oral policy depends on compliance with the protocol and this may vary between populations and healthcare settings. If the infant vomits or regurgitates the formulation within 1 hour of administration, repeating the oral dose may be appropriate. The oral route is not appropriate for preterm infants and for newborns who have cholestasis or impaired intestinal absorption or are too unwell to take oral vitamin K, or those whose mothers have taken medications that interfere with vitamin K metabolism. Parents who receive prenatal education about the importance of vitamin K prophylaxis may be more likely to comply with local procedures.

Key Words: newborn infant, vitamin K, vitamin K deficiency bleeding

Received March 30, 2016; accepted March 31, 2016.

H ealthy newborns and infants are at risk of developing severe hemorrhages and especially intracranial hemorrhages due to physiologically low concentrations of vitamin K that result in low concentrations of vitamin K—dependent clotting factors. Therefore prophylaxis against vitamin K deficiency bleeding (VKDB) is important.

The aim of this position paper is to define the condition, describe the prevalence, discuss current prophylaxis practices and outcomes, and to provide recommendations for setting up local guidelines for the prevention of VKDB in newborns and infants.

HISTORY OF HEMORRHAGIC DISEASE OF THE NEWBORN

Hemorrhagic disease of the newborn (1) was first systematically described by Charles Townsend in 1894 (2). He described 50 cases of a bleeding disorder that occurred in 0.6% of newborn infants usually on days 2 to 3. This is nowadays classified as the classic form of VKDB and mainly affects the skin, gastrointestinal tract, and brain. The case fatality rate was 62%, whereas surviving infants typically recovered within 5 days. At that time it was, however, impossible to differentiate sepsis-induced bleeding disorders such as disseminated intravascular coagulation from VKDB. The average incidence in unsupplemented populations has been estimated to be 0.25% to 1.7% (3) based on reported incidences of 0.25% (4), 0.33% (5) up to 13.9% (6) in a single study (also including hemorrhages of the circumcision wound).

The underlying pathophysiology was first described by the biochemist Henrik Dam. In 1929 he discovered a “Coagulation”
factor in chicken (coagulations vitamin, vitamin K) (7). Subsequently, prothrombin deficiency was documented in newborns with VKDB by Brinkhous et al (8) and Dam et al (9–15). Waddell et al (16) showed that vitamin K prevents hemorrhagic disease of the newborn. Vitamin K was first synthesized in 1939 (17) and in 1961 the committee on nutrition of the American Academy of Pediatrics first recommended postnatal prophylaxis for classic VKDB using 0.5 to 1.0 mg vitamin K parenterally or 1.0 to 2.0 mg orally (18). It is important to note that the incidence of VKDB in the USA had already significantly decreased over the years before this recommendation was published, probably because of the declining incidence of breastfeeding from 1930 to 1960. Human milk vitamin K concentration is significantly lower than infant formula vitamin K concentration and classic VKDB has mostly been seen in breastfed infants (19,20). The American Academy of Pediatrics recommended its formulation in 1993 (21). More recently, in 2003, intramuscular (IM) prophylaxis only using 0.5 to 1 mg vitamin K has been recommended (3). In 1966, the first reports from Thailand of a new VKDB syndrome were published that typically presented between 1 and 2 months of life and which is now classified as late VKDB. In 1977 Blanchet et al (22) who first described this syndrome, summarized their studies of 93 affected predominantly breastfed (98%) Thai infants. Their incidence of intracranial bleeding was 63%. More reports from South East Asia and Australia followed. In infants without vitamin K prophylaxis the incidence of late VKDB (per 100,000 births) has been estimated to be 4.4 in the United Kingdom, 7.2 in Germany, and as high as 72 in Thailand (23). It is important to take into consideration that VKDB occurs more frequently in the Asian population compared to the Caucasian population. This may be explained by the 6-fold higher incidence of biliary atresia in Asia compared to Western Europe (24).

In infants born to mothers using anticonvulsant drugs (eg, phenobarbital, phenytoin, carbamazepine, etc) an increased incidence of early VKDB within the first 24 hours has been observed (25,26). More recent data critically discussed this association; however, a causal link cannot be excluded (27). Postnatal IM vitamin K corrects biochemical abnormalities in these infants within 2 hours (27). Prenatal maternal vitamin K treatment has been hypothesized to prevent early VKDB in these infants (28); however, this concept still warrants further evaluation (29). Therefore, immediate postnatal IM vitamin K administration is currently regarded as the optimum VKDB prophylaxis for this group of infants.

**VITAMIN K**

Vitamin K is a family of fat-soluble 2-methyl-1,4-naphthoquinones with a variable alkyl substituent at the 3 position (19,30). Vitamin K is required for the γ-carboxylation of coagulation factors II (prothrombin), VII, IX, X, protein C, and protein S. It acts as an essential cofactor for the conversion of specific peptide-bound glutamate residues to γ-carboxyglutamate residues. The collective abbreviation for these under-carboxylated molecules is PIVKA (proteins induced by vitamin K absence), and includes, for example, PIVKA-II, which is the glutamate precursor of prothrombin (factor II). There are additional vitamin-K-dependent proteins such as osteocalcin or matrix GLA protein, the function of which is less clear.

**Relevant Forms of Vitamin K**

1. Phylloquinone (vitamin K<sub>1</sub>) is synthesized by plants and algae, for example, green leafy vegetables such as spinach, brussels sprouts, cabbage, lettuce, and broccoli. This is the only form used therapeutically in humans.
2. Multiple menaquinones (vitamin K<sub>2</sub>), synthesized by bacteria such as intestinal bacteria and found in egg yolk, chicken, beef, liver, fermented products such as cheese, and in fermented vegetables such as cabbage or natto (fermented soybeans).
3. The synthetic form menadione (vitamin K<sub>3</sub>) is no longer used for oral vitamin K prophylaxis because of potential toxicity. Hemolytic anemia has been reported in glucose-6-phosphate dehydrogenase deficient infants treated with vitamin K<sub>3</sub>.

The intestinal absorption of dietary vitamin K, mainly phylloquinone (vitamin K<sub>1</sub>), is thought to be governed by the same principles established for other fat-soluble vitamins, and in healthy adults the efficiency of absorption is about 80% (19). Phylloquinone is the major circulating form of vitamin K but in addition there are small amounts of menaquinones (vitamin K<sub>2</sub>) (19). Although phylloquinone in blood must have been derived exclusively from the diet, it is not known whether circulating menaquinones are derived from the diet, intestinal flora, or both. Human liver stores normally compromise about 90% menaquinones and 10% phylloquinone (31). Functionally, menaquinones seem to be less important because dietary phylloquinone deficiency induces subclinical signs of vitamin K deficiency without a change of hepatic menaquinone stores (32). Hepatic menaquinone stores may not be available to microsomal γ-glutamyl carboxylase (31). There is no menaquinone detectable in newborns (33–35), and at 1 year of age hepatic menaquinone stores are still significantly lower than that in adults (32,34).

Vitamin K does not easily cross the placenta and the average maternal/fetal concentration gradient is within the range of 20:1 to 40:1 (19). The fetal plasma vitamin K concentration is very low and consequently at birth concentrations of clotting factors are low. Increased PIVKA II concentrations (>10 ng/mL) have been found in the umbilical cord blood in 10% to 50% of healthy term and preterm infants, which is a biomarker of low vitamin K level (36,37). At least a transient increase in fetal vitamin K<sub>1</sub> concentration has been observed with maternal vitamin K<sub>1</sub> supplementation; however, no significant effect on vitamin K–dependent coagulation factors has been found (19). Therefore prenatal maternal vitamin K<sub>1</sub> supplementation does not prevent VKDB.

**CLASSIFICATION OF VITAMIN K DEFICIENCY BLEEDING IN NEWBORN INFANTS AND INFANTS**

VKDB of the newborn has been classified (19,38) by age of onset into early (<24 hours), classical (days 1–7) and late (>1 week <6 months), and by etiology into idiopathic and secondary in 1999 by the Pediatric and Perinatal Subcommittee of the International Society on Thrombosis and Hemostasis (39). There are few data on the relative frequencies of early, classic, and late VKDB. A regional epidemiological study from Malaysia in the 1990s, however, enables calculation of a lower threshold of the incidences (40). Within a 2-year period 42 VKDB infants were admitted to a single regional pediatric hospital likely to provide care for all such infants. In a population in which most infants were breastfed (96%) and in which vitamin K prophylaxis was infrequent (83% not supplemented) the incidences of early, classic and late VKDB were at least 1/7000, 1/4000, and 1/8000, respectively. The relative proportions were 6:10:5 (Table 1).

**VITAMIN K METABOLISM OF THE NEWBORN AND RISK FACTORS FOR VKDB**

Although plasma vitamin K<sub>1</sub> concentration is very low immediately after birth, adult levels have been recorded on days...
TABLE 1. Classification of vitamin K deficiency bleeding of the newborn infant (41)

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Time of presentation</th>
<th>Common bleeding sites (28,38,42)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early VKDB</td>
<td>0–24 h</td>
<td>Subperiosteal hemorrhage of the skull</td>
<td>Maternal drugs are a frequent cause (eg, coumarin-anticoagulants such as warfarin, enzyme-inducing drugs, eg, anticonvulsants, and some tuberculosstatic drugs) (28,43–46)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(cephalohematoma), intracranial, brain, intrathoracic, intra-abdominal, umbilical stump</td>
<td>Mainly idiopathic, maternal drugs (18,42,47,48)</td>
</tr>
<tr>
<td>Classic VKDB</td>
<td>2–7 days (2)</td>
<td>Gastrointestinal tract, skin, adrenal gland, nose, wound from circumcision, intracranial, umbilical stump</td>
<td>Most commonly presenting feature of underlying disease resulting in reduced vitamin K absorption (eg, cystic fibrosis, biliary atresia, or other liver diseases with cholestasis), occasionally idiopathic</td>
</tr>
<tr>
<td>Late VKDB</td>
<td>2–12 wk (23,49–52)</td>
<td>Intracranial, skin, gastrointestinal</td>
<td></td>
</tr>
</tbody>
</table>

VKDB = vitamin K deficiency bleeding.

3 to 4 following supplementation (53,54) and levels are higher in formula-fed infants compared to breastfed infants. Human milk vitamin K concentration (median 2.5 μg/L [0.85–9.2 μg/L]) is significantly lower than currently available formula milk (4–25 μg/100 kcal approximately corresponding to 24–175 μg/L) (55,56). On average daily vitamin K intake of breastfed infants is <1 μg within the first 6 months of life, whereas the intake of formula-fed infants is on average up to 100 times higher (57). With regard to global coagulation tests such as prothrombin time (PT) there is no significant difference between breast- and formula-fed infants (53,57). PIVKAs are, however, much more commonly reported in breastfed infants (54,58). Formula vitamin K1 exceeds the recommended vitamin K intake of at least 5 μg/day (30). Because breastfeeding fails to provide this intake, and because VKDB is much more common in un-supplemented breastfed infants it is recommended that all infants receive some form of supplementation.

The major risk factor for classic VKDB is a low plasma vitamin K concentration, due to low levels in breast milk and/or inadequate vitamin K prophylaxis in newborn infants, all of whom are vitamin K deficient at birth. The effects are manifest by the presence of PIVKA and lower levels of vitamin K–dependent coagulation factors and of other vitamin K–dependent proteins such as the osteoblast product, osteocalcin. Elevated PIVKA-II levels (>10 ng/mL) have been found in the umbilical cord blood of 10% to 50% of healthy preterm or term newborn infants (36,37). At the age of 4 to 5 days PIVKA have been found in up to 70% of healthy unsupplemented newborn infants (59). In addition, factor II and VII activity has been reported to be reduced in infants who did not achieve a breastfeeding volume of 100 mL/kg at 3 to 4 days of age (59). Therefore classic VKDB may at least partially be a consequence of insufficient or delayed establishment of breastfeeding (59). Intramuscular or oral (1.0 mg) vitamin K prophylaxis has been found to be equally effective in improving biochemical indices of coagulation status (PIVKA) at 1 to 7 days (60–62).

The major risk factors for late VKDB are low plasma vitamin K concentrations due to insufficient vitamin K prophylaxis, and breastfeeding combined with cholestatic liver impairment, which may be subclinical or transient (63,64).

SAFETY OF VITAMIN K PREPARATIONS

There are no data to determine the upper safe level of vitamin K in general in infancy. In 1992 Jean Golding et al (65) published epidemiological data suggesting that certain forms of childhood cancer were associated with IM vitamin K injections. The speculated biological mechanism of carcinogenesis (induction of sister chromatid exchange) did not accord with other information from the literature about in vivo effects of vitamin K or other tests of carcinogenicity (21). Most expert opinion currently suggest that a causal relation between IM injection of vitamin K and childhood cancer is not plausible (3,23) and the hypothesized association has never been confirmed in other large epidemiological studies. On the contrary, due to the lack of large randomized studies, this hypothesis has not been disproved (66,67).

**DIAGNOSIS OF VITAMIN K DEFICIENCY BLEEDING**

A confirmed case of VKDB should fulfill the criteria of having a PT that is ≥4 times the control value and display at least one of the following (68):

1. Normal or raised platelet count, normal fibrinogen, and absent fibrin degradation products.
2. PT returning to normal within 30 to 20 minutes after intravenous vitamin K administration (69,70). In general there is no need for supplementation of coagulation factors (41).
3. PIVKA (usually that of factor II) level exceeding normal controls (41).

**PROPHYLAXIS FOR VITAMIN K DEFICIENCY BLEEDING**

**Intramuscular Injection of Vitamin K**

In 1961 and 1993 the American Academy of Pediatrics recommended early postnatal vitamin K prophylaxis using 0.5 to 1.0 mg vitamin K parenteral or 1.0 to 2.0 mg orally (18,21). In 2003 the IM injection of 1 mg vitamin K at birth was proposed as standard of care of healthy newborn infants (3). The argument in favor of IM prophylaxis was that a single injection was more reliably administered, and likely to result in a depot supply over the ensuing weeks of risk. Therefore this policy is widely used worldwide. Epidemiological surveillance data have shown that this policy virtually prevents classic and late VKDB (incidence <0.2/100,000) (23,68,71,72). Despite the use of postnatal 1 mg IM injection there are still some rare cases of late VKDB, which warrant further evaluation (41,73–75). Adverse effects of IM vitamin K injections such as local infections have never been systematically assessed; however, it is likely to be painful for newborn infants.
Oral Supplementation of Vitamin K

Worldwide, oral supplementation became more widespread after the article by Golding et al in 1992 (65) and is still used despite the association between IM vitamin K and childhood cancer never being reconfirmed (66,67).

Oral vitamin K prophylaxis policies vary in terms of dose and frequency, and appear to offer virtually complete protection from early and classic bleeding. The associated incidence of late VKDB has, however, repeatedly been observed to be higher when compared to a single 1 mg IM dose at birth (23,68,76,77).

In order to prevent late VKDB in addition to early and classic bleeding in Europe 3 oral prophylaxis patterns have been developed and evaluated. Because there are no randomized head-to-head comparison trials, and such trials will probably never be conducted, efficiency of individual policies can only be assessed by surveillance data. These data are always at risk of underreporting (78).

In Germany using a 3 × 2 mg oral vitamin K$_1$ prophylaxis policy an incidence of late VKDB of 0.44/100,000 (95% CI 0.19–0.87) has been reported (79). Taking an underreporting bias of 57% (38%–76%) (78) into account the estimated incidence was 0.73/100,000 (95% CI 0.23–2.2). In Switzerland in 458,184 newborn infants in 2005 to 2011 one early (18 hours of age) and 4 late VKDB cases were observed (80). All infants were breastfed and in all but one of the infants the parents declined vitamin K prophylaxis. In the remaining infant only the first 2 oral vitamin K doses had been given. All infants with late VKDB had some cholestatic liver disease. Therefore, in infants with complete VKDB prophylaxis (oral 3 × 2 mg) there was a combined risk for classic and late VKDB of 0/100,000 (95% CI 0–0.81) (80). The degree of underreporting in the Swiss study is, however, unknown. At 24 weeks of age an additional fully breastfed infant developed very late VKDB, in the absence of cholestatic liver disease. Of note these published efficacy data depended on administration of oral vitamin K by healthcare professionals (Table 2).

Taking these data together, there is some evidence that the oral 3 × 2 mg policy may be less effective than a single postnatal 1 mg IM injection (73,79). In all infants with late VKDB, there was a combination of previously unknown cholestatic liver disease together with breastfeeding. In infants with conjugated hyperbilirubinemia intestinal absorption of oral vitamin K prophylaxis is unreliable (90).

In contrast to promising early data (68,91) on the previous Dutch oral policy (1 mg after birth followed by 25 µg/day for weeks 2–13) later extensive surveillance data suggested that this policy was associated with the highest incidence of late VKDB of all the policies listed in the table above (85). Concerning the cause of the 6 reported cases of late VKDB there was 1 case of idiopathic VKDB, 1 case in association with breast milk jaundice, and 4 cases of previously unrecognized cholestasis because of biliary atresia. In the Netherlands annually approximately 5 infants experienced serious hemorrhage. After evaluation of current literature and advice from The Health Council of the Netherlands, vitamin K dosage was adapted for all breastfed infants from day 8 to 3 months (12th week of life) following birth by raising the daily dose from 25 to 150 µg/day (84). This policy, however, still warrants epidemiological evaluation.

In Denmark, no cases of VKDB were reported during a period when the following policy was used: 2 mg oral at birth and 1 mg weekly orally administered vitamin K during the first 3 months of life. This was given to at least 400,000 infants during a 9-year surveillance period (88,89). Importantly, in infants with previously unknown biliary atresia this regimen seemed to be as effective as the single postnatal 1 mg IM injection (92). Weekly oral administration of 1 mg requires a higher degree of parental compliance than an oral policy of 3 × 2 mg vitamin K$_1$, postnatal, on day 3 to 10, and at 4 to 6 weeks. In 2000 in Denmark the National Board of Health (Sundhedsstyrelsen) evaluated the literature and concluded that IM prophylaxis gave better protection against VKDB, alongside a recognition that IM injection had no apparent relation with

<p>| TABLE 2. Recent surveillance data of vitamin K deficiency bleeding prophylaxis policies (efficacy is given ATP) |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|</p>
<table>
<thead>
<tr>
<th>VKDB prophylaxis policy</th>
<th>Country</th>
<th>Evaluated in N infants</th>
<th>Associated classic/late VKDB incidence per 100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral prophylaxis 3 × 2 mg</td>
<td>Germany</td>
<td>1,817,769</td>
<td>0.44 (95% CI 0.19–0.87) (79); taking underreporting (78) into account the estimated incidence may be 0.73 (95% CI 0.23–2.2) 76</td>
</tr>
<tr>
<td>3 × 2 mg oral (postnaturally, days 3–10 and weeks 4–6)</td>
<td>Switzerland</td>
<td>458,184</td>
<td>0.0 (95% CI 0.0–0.81) (80)</td>
</tr>
<tr>
<td>Total</td>
<td>2,275,953</td>
<td>8 Cases</td>
<td></td>
</tr>
<tr>
<td>1 mg IM prophylaxis</td>
<td>New Zealand</td>
<td>654,000</td>
<td>0.16 (95% CI 0–0.46) (72)</td>
</tr>
<tr>
<td>1 mg IM postnaturally</td>
<td>UK</td>
<td>1,700,000</td>
<td>0.24 (0.0–0.35) (73)</td>
</tr>
<tr>
<td>No uniform policy (73,81–83) most commonly 1 mg IM postnaturally but several regions use oral Total</td>
<td>2,354,000</td>
<td>5 cases</td>
<td></td>
</tr>
<tr>
<td>Policies no longer in reported use</td>
<td>The Netherlands (until 2011) (84)</td>
<td>187,910</td>
<td>3.2 (95% CI 1.2–6.9) (85)</td>
</tr>
<tr>
<td>1 mg oral postnaturally; 25 µg/day oral days 8–90</td>
<td>Denmark (until 2000) (86,87)</td>
<td>400,000</td>
<td>0.0 (95% CI 0.0–0.9) (88,89)</td>
</tr>
</tbody>
</table>

CI = confidence interval; VKDB = vitamin K deficiency bleeding.
the risk of cancer. Therefore, postnatal 1 mg IM vitamin K prophylaxis was recommended as the standard of care (86). In addition at this time it was no longer possible to obtain the oral preparation of vitamin K because of technical problems (73). This recommendation was reconfirmed in 2010 (87).

In Great Britain in 2006 routine vitamin K prophylaxis was recommended by the National Institute for Clinical Excellence (NICE) to be administered as a single dose of 1 mg IM as this is the most efficacious and cost-effective method of administration (83). Alternatively (second line), 2 doses of 2 mg oral vitamin K should be given at birth and at 4 to 7 days and a third dose in exclusively breastfed infants only at 1 month. As a third alternative, the Danish regimen may be used (81,82).

Finally it is important to consider that although there are no randomized head-to-head comparison trials comparing different policies, these are unlikely given the low incidence of VKDB in supplemented infants.

VITAMIN K PREPARATIONS

The available data do not permit the recommendation of one specific vitamin K preparation. Pharmacokinetic studies of a mixed micellar vitamin K preparation suggested a higher oral bioavailability compared with a normal vitamin K preparation (93). This theoretical advantage of the pediatric mixed micellar preparation of vitamin K has never been demonstrated in randomized controlled trials (76). Of note, the data suggesting better oral bioavailability were based on only 3 children experiencing cholestasis (93). In Germany surveillance of late VKDB observed no significant benefit of the mixed micellar vitamin K preparation (RR 0.58; 95% CI 0.23–1.47). Because of the low incidence of late VKDB (18 infants) the sample size of 3.2 million children was, however, insufficient to detect a significant difference (79).

In contrast to IM injections, an oral vitamin K policy may be easier to achieve, and may also be more acceptable to some parents and healthcare providers. Unexpected absorption, unclear compliance with repeated dosing, insufficient parental health access (eg, minorities, asylum seeker, and refugees), and incomplete application (eg, posseting or vomiting that requires repeat administration) remain important disadvantages. A variety of different products are used; however, caution must be taken, because a number of these may not have undergone pharmaceutical quality control.

The pharmacokinetics of intravenous (IV) vitamin K are not well known, but it is likely to be similar to that of vitamin K given orally. IV administration does not seem to bring the same efficiency as the IM route for the prevention of the late form of VKDB especially if the injection is not repeated (73). The slower increase in urinary excretion of vitamin K metabolites after IM injection compared with an equivalent dose given by the IV route gives support to a depot effect whereby lipophilic vitamin K leaches out slowly from the muscular site of injection into the circulation. In contrast the rapid increase in urinary excretion of vitamin K metabolites after IV injection suggest a more rapid but transient effect of the IV injection (94). IV vitamin K1 administration may be considered in preterm infants, sick term infants, or infants with cholestatic liver disease. The use of IV vitamin K1 has, however, not been extensively examined for prophylaxis of VKDB.

CONCLUSIONS

(1) VKDB due to physiologically low vitamin K plasma concentrations is a serious risk for newborn and young infants.
(2) Adequate vitamin K supplementation prevents the vast majority of VKDB.
(3) Intramuscular application is the preferred route for efficiency and reliability of administration.

Data from some countries suggest IM application may be more effective than 3 × 2 mg oral prophylaxis for prevention of late VKDB (68,71,79,95). Analysis of the more recent epidemiological data obtained from >4.5 million children (Table 2) does not suggest a significant difference between these 2 options with regard to the efficacy in prevention of late VKDB.

RECOMMENDATIONS

(1) All newborn infants should receive vitamin K prophylaxis.
(2) Vitamin K prophylaxis and the mode of administration should be documented.
(3) Parental refusal of vitamin K prophylaxis after adequate information is provided should be documented especially because of the risk of late VKDB (96,97).
(4) Healthy newborn infants should either receive:
   (a) 1 mg of Vitamin K1 by IM injection at birth, or
   (b) 3 × 2 mg Vitamin K1 orally at birth, at 4 to 6 days and at 4 to 6 weeks. or
   (c) 2 mg Vitamin K1 orally at birth, and a weekly dose of 1 mg orally for 3 months.
(5) The success of an oral policy depends on compliance with the protocol and this may vary between populations and healthcare settings. If the infant vomits or regurgitates the formulation within 1 hour of administration, repeating the oral dose may be appropriate.
(6) The oral route is not appropriate for preterm infants and for newborns who are unwell, have cholestasis or impaired intestinal absorption or are unable to take oral vitamin K or whose mothers have taken medications that interfere with vitamin K metabolism.

General Advice

(1) Healthcare providers must develop local policies, procedures, and guidelines for the administration of prophylactic vitamin K to infants, and conduct regular audit to ensure compliance and efficacy. The date, dose, and route of administration must be recorded in the infant’s personal health record (expert opinion of the committee).
(2) Parents who receive information during the antenatal period about the importance of vitamin K prophylaxis may be more likely to comply with local procedures (98).

FUTURE RESEARCH TOPICS

(1) Robust national surveillance data of VKDB, which require accurate documentation of policies and procedures.
(2) Efficacy and quality control of individual vitamin K products used for supplementation.

REFERENCES


34. Mihatsch et al. JPGN • Volume 63, Number 1, July 2016


